Article

A Single-Cell Atlas Identifies Pretreatment Features of Primary Imatinib Resistance in Chronic Myeloid Leukemia

2022-11-15

Abstract excerpt

Response heterogeneity to targeted therapies is a major barrier to achieving optimal outcomes in a broad range of myeloproliferative neoplasms (MPN) with druggable oncogenes. This remains the case in chronic myeloid leukemia (CML) where pharmacologic targeting of the causative BCR-ABL1 kinase with tyrosine kinase inhibitors (TKI) elicits highly heterogeneous responses. The reasons why some patients enjoy deep mole...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 6f023861-69a7-5780-a972-f68c51c38a14
DOI: 10.1182/blood-2022-165758

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A Single-Cell Atlas Identifies Pretreatment Features of Primary Imatinib Resistance in Chronic Myeloid LeukemiaDOI 10.1182/blood-2022-165758Read

A Single-cell Atlas Identifies Pretreatment Features of Primary Imatinib Resistance in Chronic Myeloid LeukemiaSemantic proximity Read

Single cell multi-omics analysis of chronic myeloid leukemia links cellular heterogeneity to therapy responseSemantic proximity Read

Single-cell landscape of innate and acquired drug resistance in acute myeloid leukemiaSemantic proximity Read

Single-cell multiomics analysis of chronic myeloid leukemia links cellular heterogeneity to therapy responseSemantic proximity Read

Single-cell transcriptomics-guided development of flow cytometric tests predicting chronic myeloid leukemia blast crisis transformation at chronic phase diagnosisSemantic proximity Read

Single-cell panleukemia signatures of HSPC-like blasts predict drug response and clinical outcomeSemantic proximity Read

Transcriptional and phenotypic heterogeneity underpinning venetoclax resistance in AMLSemantic proximity Read

Multiomic single-cell analysis identifies von Willebrand factor and TIM3-expressing <i>BCR-ABL1</i> <sup>+</sup> CML stem cellsSemantic proximity Read

Decoding leukemia at the single-cell level: clonal architecture, classification, microenvironment, and drug resistanceSemantic proximity Read

Dynamic heterogeneity towards drug resistance in AML cells is primarily driven by epigenomic mechanism unveiled by multi-omics analysisSemantic proximity Read

Dynamics of Leukemic Blast and Immune Cell Populations in Acute Myeloid LeukemiaSemantic proximity Read

Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemiaSemantic proximity Read